Infliximab: A Review of its Use in the Treatment of Crohn’s Disease

摘要: Infliximab is a chimeric monoclonal antibody to human tumor necrosis factor alpha. While its use was developed in the treatment of rheumatologic diseases effects on Crohn’s disease have revolutionized management this chronic illness. has both immune and epithelial cells leading reduction gut inflammation collagen deposition which promotes wound healing. Large randomized trials proven efficacy drug luminal fistulizing disease. Over time our understanding formation long-term tolerability refined infliximab, eliminating episodic dosing utilizing concomitant immunomodulator therapy improve efficacy. Questions remain regarding top-down strategies, length therapy, cost, surgical procedures, determination patients will respond best any strategy chosen.